Genetic Predisposition and Response Variability in Endurance Training Programs

Endurance train responsiveness varies significantly between individuals due to genetic predisposition (GP). Heritability estimates (h²) for VO₂max train response range 40–70%, indicating strong GP influence. Key polymorphisms in ACE (I/D), ACTN3 (R577X), PPARA, PPARD, PGC-1α (PPARGC1A), and AMPD1 associate with aerobic capacity, mitochondrial biogenesis (MB), and fatigue resistance. ACE I allele correlates with endurance phenotype, improved O₂ utilization, and higher baseline VO₂max. ACTN3 XX null genotype reduces fast-twitch fiber expression, favoring endurance over power. PPARA rs4253778 G allele enhances fatty acid oxidation (FAO). PPARD rs2016520 C allele upregulates oxidative metabolism genes. PGC-1α Gly482Ser (rs8192678) minor allele (Ser) linked to reduced MB and attenuated train response. AMPD1 Gln12Ter (rs17602729) variant improves endurance efficiency via adenosine modulation. Polygenic scores (PGS) aggregate multiple SNPs to predict train outcomes; PGS for VO₂max explains ~12–20% of variance. Epistatic interactions (e.g., ACE×ACTN3) modulate phenotype expression. Non-genetic modulators include baseline fitness, age, sex, nutrition (e.g., nitrate intake), sleep, and training load periodization. High responders (HR) exhibit ≥500 mL/min VO₂max increase post-6mo train; low responders (LR) <100 mL/min. LR incidence ~20% in cohort studies. Transcriptomic profiling shows HR upregulate mitochondrial, angiogenic, and glucose transport pathways (e.g., VEGF, GLUT4). LR show blunted gene expression shifts. Methylation changes in PGC-1α, TFAM post-training correlate with MB. miRNAs (e.g., miR-696) regulate PGC-1α expression. Gut microbiome (GM) composition (e.g., Veillonella abundance) may influence lactate-to-propionate conversion, enhancing endurance. CRP, IL-6 SNPs (inflammatory markers) affect recovery kinetics. Personalized training (PT) uses GP + biomarkers to optimize program design. Commercial genetic testing (e.g., DNAFit, Athletigen) provides PGS-based recs but lacks clinical validation. Ethical concerns: genetic determinism, data privacy, misinterpretation. Current SoA: RCTs (e.g., HERITAGE, DREW) confirm GP role; machine learning (ML) models integrate genomic, epigenomic, and phenomic data to predict individual response. Limitations: Eurocentric bias in GWAS, small effect sizes per SNP, G×E complexity. Pitfalls: overreliance on single SNPs, ignoring epigenetics, misapplication of PGS in youth athletes. Future: multi-omics integration, longitudinal monitoring, dynamic models adapting to G×E changes. Applications: talent ID (cautiously), injury risk stratification (e.g., COL5A1 for soft tissue integrity), periodization tuning, nutritional genomics (e.g., C677T MTHFR for folate needs). Best practice: combine GP with regular performance testing, HRV, blood markers (e.g., ferritin, CK), and subjective feedback. GP informs but doesn’t dictate train design; modifiable factors remain primary levers.